005250.KS

Green Cross Holdings Corporation [005250.KS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

005250.KS Stock Summary

Top 10 Correlated ETFs

005250.KS

Top 10 Correlated Stocks

005250.KS

In the News

005250.KS Financial details

Company Rating
-
Market Cap
717.6B
Income
-66.57B
Revenue
2057.94B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
165
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-23.87
Forward P/E
-
PEG
1.12
P/S
0.35
P/B
0.71
P/C
-
P/FCF
-3.5
Quick Ratio
-
Current Ratio
0.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.47K
EPS next Y
-
EPS next Q
-
EPS this Y
-191.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.18%
Revenue last 5Y
6.18%
Revenue Q/Q
-0.03%
EPS Q/Q
13.13%
-
-
-
-
SMA20
0.83%
SMA50
22.1%
SMA100
14.65%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-3%
ROC
-0.01%
Gross Margin
30%
Oper. Margin
-1%
Profit Margin
-1%
Payout
-104%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12920.0-17990.0
52W High
-6.95%
52W Low
+29.57%
RSI
59.7
Rel Volume
0.7
Avg Volume
62.41K
Volume
43.89K
Perf Week
1.89%
Perf Month
18.98%
Perf Quarter
3.98%
Perf Half Y
4.76%
-
-
-
-
Beta
0.934
-
-
Volatility
325.35%, 679.26%
Prev Close
-0.3%
Price
16740
Change
0.66%

Something similar

Top by Market Cap
1YD.DE
VFINX
BRK-B
V
ABEC.DE
Top Correlated ETFs
270800.KS
SLVP
144600.KS
SIL
SILJ
Top Correlated Stocks
005500.KS
CCUR
HIAG.SW
001940.KS
015890.KS
Similar Market Cap
032350.KS
601138.SS
INVE-A.ST
003540.KS
2628.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 62.41K
  • Market Capitalization 717.6B
  • Employee 165
  • CEO Mr. Il-Sup Huh Ph.D.
  • Headquarters Yongin-Si,KR
  • IPO Date 2000-01-04
  • Website https://www.greencross.com

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.